Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study for Solid Metastatic Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed breast cancer or other cancer which is persistent and metastatic or recurrent and metastatic.~* Patients with a history of treatment for other prior malignancy will be eligible, provided they remain disease-free \> 2 years after initial treatment, or were treated for non-melanoma skin cancer, or in situ cervical cancer.~* Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of larger in their largest diameter.~* Age \>18 years.~* ECOG performance status \<2 (Karnofsky \>50%).~* Life expectancy \> 3 months.~Exclusion Criteria:~* Patients who have had immunotherapy within 4 weeks prior to entering the study.~* Patients who have had prior allergic reaction to GM-CSF~* Patients on steroid therapy or other immunosuppressive therapy.~* Patients undergoing therapy with other investigational agents.~* Patients with known brain metastases can be included in this clinical trial but brain lesions are not eligible as target or non target lesion.~* Uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the past 6 months, unstable angina pectoris, or unstable cardiac arrhythmia requiring assessment for clinical intervention.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Radiation therapy (Type: EXPERIMENTAL): Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol

Based on this trial design, predict the completion outcome and termination type (if applicable).